Clinical trials: Metabolic Biomarkers
Periodontal Disease
Study on Biomarkers of Periodontitis and Type 2 Diabetes Mellitus in Males and Females 30 - 70 Years of Age
The purpose of this study is to learn about the interactions of markers of type 2 diabetes (T2DM) and periodontitis (PD). Study VPE00001 is a multi-center cross-sectional study.
- Trial name
- NCT06582056
- Testing
- Investigational Procedure
- Where
- 4 sites in United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Alzheimer Disease, Mild Cognitive Impairment
Clinical Feasibility of Speech Phenotyping for Remote Assessment of Neurodegenerative and Psychiatric Disorders
The primary objective of the study is to evaluate the feasibility of eliciting continuous narrative speech in different neurodegenerative and psychiatric indications, using remote, self-administered speech tasks, as measured by…
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia With Lewy Bodies, Dementia, Vascular
- Trial name
- RHAPSODY (NCT04939818)
- Where
- 2 sites in United Kingdom
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Gaucher Disease
A Study Measuring Substances Potentially Indicating Bone Problems in Adults With Type 1 Gaucher Condition
Substances in the body, so-called biomarkers, can help predict the severity of Gaucher disease (GD)-related bone problems in adults.
- Trial name
- NCT05702814
- Testing
- No Intervention
- Where
- Spain
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Takeda
Healthy, Type 2 Diabetes Mellitus
Type 2 Diabetes Glucose Biomarker Study With a Continuous Glucose Monitoring System
Current gold standard methodologies for diagnosing type 2 diabetes (T2D) or prediabetes can be unreliable and inaccurate, and require the need for multiple different tests for comparison.
- Trial name
- NCT04529239
- Testing
- Abbott Freestyle Libre Pro
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Klick Inc.
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Multiple System Atrophy
A Biomarker Study of ATH434 in Participants With MSA
This study will assess the safety and efficacy of ATH434 in participants with a clinical diagnosis of Multiple System Atrophy
- Trial name
- NCT05864365
- Testing
- ATH434
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Alterity Therapeutics
Obesity & Overweight, Weight Loss
GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study
This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health…
- Conditions
- Obesity & Overweight, Weight Loss, Preventative Health, Body Weight
- Trial name
- FLOURISH (NCT07588984)
- Testing
- Noom Weight, Free Tier, Education-only control
- Where
- United States
- Volunteers
- 2,310 people
- Sponsor
- Noom Inc.
Renal Fanconi Syndrome, Photophobia
Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)
Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Cystinosis disease from the blood
- Conditions
- Renal Fanconi Syndrome, Photophobia, Hypophosphatemia
- Trial name
- BioCystinosis (NCT02837523)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Lipoprotein Lipase Deficiency, Inborn Error of Lipid Metabolism
Biomarker for Homozygous Familial Hypercholesterolemia (BioHoFH)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Homozygous familial Hypercholesterolemia from blood
- Conditions
- Lipoprotein Lipase Deficiency, Inborn Error of Lipid Metabolism, Corneal Arcus
- Trial name
- BioHoFH (NCT03198897)
- Where
- 4 sites in Germany, India and 1 more
- Sponsor
- CENTOGENE GmbH Rostock
Inborn Errors of Metabolism, Biomarker
Biomarkers for Inborn Errors of Metabolism
International, multicenter, observational, longitudinal study to identify or monitor Inborn Error of Metabolism disease biomarkers and to explore the clinical robustness, specificity, and long-term variability of these biomarkers
- Trial name
- BioMetabol (NCT04098198)
- Where
- 13 sites in Albania, Egypt and 6 more
- Volunteers
- 462 people
- Sponsor
- CENTOGENE GmbH Rostock
Diabetes Mellitus, Type 2
Study In Postmenopausal Women With Type 2 Diabetes Looking At Approved Diabetes Drugs And How They Affect Bone Health
The purpose of this study is to determine the effects of rosiglitazone on the bone in postmenopausal women with type 2 diabetes mellitus
- Trial name
- NCT00679939
- Testing
- Rosiglitazone, Metformin
- Where
- 42 sites in United States, Argentina and 6 more
- Volunteers
- 226 people
- Sponsor
- GlaxoSmithKline
Morquio Syndrome, Accumulation of Mucopolysaccharides
Biomarker for Morquio Disease (BioMorquio)
Development of a new MS-based biomarker for the early and sensitive diagnosis of Morquio disease from plasma
- Conditions
- Morquio Syndrome, Accumulation of Mucopolysaccharides, Morquio Syndrome A, Morquio B Disease
- Trial name
- BioMorquio (NCT01457456)
- Where
- 5 sites in Egypt, Germany and 2 more
- Sponsor
- CENTOGENE GmbH Rostock
Amyotrophic Lateral Sclerosis (ALS)
Generation of Cell Banks and Biomarker Isolation From Patients With Amyotrophic Lateral Sclerosis (ALS) (HCD-SLA)
The aim of this research is to establish different cell banks from patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- HCD-SLA (NCT07099066)
- Testing
- sampling blood
- Volunteers
- 50 people
- Sponsor
- Human Cell Design
Type 2 Diabetes Mellitus, Metabolic Syndrome
Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
This is a Phase 2, multi-center, double-blind, placebo-controlled study of the safety and effect of PBI-4050 at doses ranging from 400 mg to 1200 mg on relevant biomarkers in subjects with inadequately-controlled T2DMS on stable…
- Trial name
- NCT03081598
- Testing
- PBI-4050
- Where
- 11 sites in Canada
- Volunteers
- 104 people
- Sponsor
- Liminal BioSciences Ltd.
Osteopenia, Osteoporosis
Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women
The primary objective of this clinical trial is to determine the effects of hesperidin on biochemical markers of bone in post-menopausal women.
- Trial name
- NCT00545116
- Testing
- Hesperidin
- Where
- Malaysia
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Chronic Smokers, Hyperlipidemia
Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia
The purpose of this study is to investigate the efficacy and safety of dietary supplements (BioTurmin, BioTurmin-WD and MaQxan) on cotinine level and oxidative stress marker in chronic smokers having mild to moderate…
- Trial name
- NCT02203227
- Testing
- BioTurmin (Curcuma longa rhizomes extract), BioTurmin-WD (Water dispersible curcuminoids), MaQxan
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Olive Lifesciences Pvt Ltd
Celiac Disease
Study of the Safety, Tolerability, Pharmacokinetics and Biomarker of DONQ52 in Celiac Disease Patients
This study is to characterize the safety and tolerability of an investigational drug called DONQ52 and consists of a single ascending dose part (Part A) and a multiple ascending dose part (Part B) in well-controlled celiac…
- Trial name
- NCT05425446
- Testing
- DONQ52
- Where
- 21 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Chugai Pharmaceutical
Fabry Disease
Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease
Fabry Disease (FD) is a rare X-linked lysosomal storage disorder (LSD) caused by mutations in the GLA gene which translates into decreased activity or lack of function of the enzyme alpha-galactosidase A (α-GAL A) and…
- Trial name
- NCT03228940
- Testing
- RVX000222
- Where
- Canada
- Sponsor
- Resverlogix Corp
Obesity
Effects of Fenofibrate on the Safety, Toleration and Efficacy Biomarkers of CP-742,033
The purpose of this study is to determine whether fenofibrate effects the toleration, safety, or efficacy biomarkers of CP-742,033, a drug being developed for the treatment of obesity.
- Trial name
- NCT00376285
- Testing
- CP-742,033, Fenofibrate
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Farber's Lipogranulomatosis, Ceramidase Deficiency
Biomarker for Farber Disease (BioFarber)
Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood
- Conditions
- Farber's Lipogranulomatosis, Ceramidase Deficiency, Hepatomegaly, Splenomegaly
- Trial name
- BioFarber (NCT02298634)
- Where
- 3 sites in Egypt, Germany and 1 more
- Sponsor
- CENTOGENE GmbH Rostock